Reporting owner · CIK 0001682093

OrbiMed Advisors Israel II Ltd

SEC Form 4 history for the last 180 days across 1 company, 19 transactions and 1 filing.

DIRADARx Pharmaceuticals, Inc.
Open-market transaction mix100% buys3 buys · 0 sales

Period: Last 180 days

Trade dates in this period: Sep 28, 2026 – Sep 28, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings1Form 4 records
Buying$16.2M3 purchases
Selling$00 sales
Net value+$16.2MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
OrbiMed Advisors Israel II Ltd transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
Derivative securitySEC filing ↗
$0View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$10.0MView disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$1.05MView disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$5.10MView disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →
ADRXADARx Pharmaceuticals, Inc.
Director
DIR
Conversion
Form 4 code C. Conversion of a derivative security.
SEC filing ↗
—View disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a buy at ADARx Pharmaceuticals, Inc. on Sep 28, 2026 valued at $9,999,995.

Review SEC filing
Latest sale

No open-market insider sale is available.

Monthly open-market activity

Last 1 reported month · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Sep 202630$16,150,000$0+$16,150,000

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$5.38M
Median P/S size$5.10M
Direct0
Indirect19
Sep 28, 2026unknown

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

11 observations · Sep 28, 2026 – Sep 28, 2026. Window ends at the latest available report, not today.

Selected observation · Sep 28, 2026588,235 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Sep 28, 202610,690,530Sep 30, 2026View transaction
Sep 28, 202612,691,492Sep 30, 2026View transaction
Sep 28, 202613,461,093Sep 30, 2026View transaction
Sep 28, 202614,025,280Sep 30, 2026View transaction
Sep 28, 202614,325,529Sep 30, 2026View transaction
Sep 28, 20267,127,019Sep 30, 2026View transaction
Sep 28, 20268,460,994Sep 30, 2026View transaction
Sep 28, 20268,974,061Sep 30, 2026View transaction
Sep 28, 20269,230,509Sep 30, 2026View transaction
Sep 28, 20269,292,025Sep 30, 2026View transaction
Sep 28, 2026588,235Sep 30, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

OrbiMed Advisors Israel II Ltd Insider Activity FAQ

SEC Form 4 context

Who is OrbiMed Advisors Israel II Ltd?

OrbiMed Advisors Israel II Ltd is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001682093.

Which companies has OrbiMed Advisors Israel II Ltd reported transactions for?

ADARx Pharmaceuticals, Inc., Adicet Bio, Inc.

When was OrbiMed Advisors Israel II Ltd's latest insider buy?

The insider reported a buy at ADARx Pharmaceuticals, Inc. on Sep 28, 2026 valued at $9,999,995.

When was OrbiMed Advisors Israel II Ltd's latest insider sale?

No open-market insider sale is recorded in the last 180 days. Earlier filings are outside the visible history.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.